Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Epidemiology

Pathology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(15)00817-x

Other Formats

PDF